Soligenix (SNGX) Competitors $1.79 -0.02 (-1.10%) Closing price 04:00 PM EasternExtended Trading$1.80 +0.01 (+0.84%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNGX vs. LEXX, RVPH, TAOX, SYBX, APLM, FNCH, CTXR, PRPH, THAR, and ASBPShould you be buying Soligenix stock or one of its competitors? The main competitors of Soligenix include Lexaria Bioscience (LEXX), Reviva Pharmaceuticals (RVPH), Synaptogenix (TAOX), Synlogic (SYBX), Apollomics (APLM), Finch Therapeutics Group (FNCH), Citius Pharmaceuticals (CTXR), ProPhase Labs (PRPH), Tharimmune (THAR), and Aspire Biopharma (ASBP). These companies are all part of the "pharmaceutical products" industry. Soligenix vs. Its Competitors Lexaria Bioscience Reviva Pharmaceuticals Synaptogenix Synlogic Apollomics Finch Therapeutics Group Citius Pharmaceuticals ProPhase Labs Tharimmune Aspire Biopharma Soligenix (NASDAQ:SNGX) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership. Which has more risk & volatility, SNGX or LEXX? Soligenix has a beta of 1.95, meaning that its share price is 95% more volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Which has better earnings and valuation, SNGX or LEXX? Lexaria Bioscience has higher revenue and earnings than Soligenix. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoligenix$120K63.99-$8.27M-$3.80-0.47Lexaria Bioscience$460K37.91-$5.80M-$0.67-1.33 Do analysts rate SNGX or LEXX? Soligenix currently has a consensus price target of $6.00, suggesting a potential upside of 235.20%. Lexaria Bioscience has a consensus price target of $4.00, suggesting a potential upside of 348.68%. Given Lexaria Bioscience's higher probable upside, analysts plainly believe Lexaria Bioscience is more favorable than Soligenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor SNGX or LEXX? In the previous week, Soligenix had 15 more articles in the media than Lexaria Bioscience. MarketBeat recorded 17 mentions for Soligenix and 2 mentions for Lexaria Bioscience. Soligenix's average media sentiment score of 0.82 beat Lexaria Bioscience's score of 0.38 indicating that Soligenix is being referred to more favorably in the media. Company Overall Sentiment Soligenix Positive Lexaria Bioscience Neutral Is SNGX or LEXX more profitable? Soligenix has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,849.19%. Lexaria Bioscience's return on equity of -157.22% beat Soligenix's return on equity.Company Net Margins Return on Equity Return on Assets SoligenixN/A -274.76% -129.20% Lexaria Bioscience -1,849.19%-157.22%-133.69% Do insiders & institutionals have more ownership in SNGX or LEXX? 3.6% of Soligenix shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 3.1% of Soligenix shares are held by insiders. Comparatively, 26.4% of Lexaria Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummarySoligenix and Lexaria Bioscience tied by winning 7 of the 14 factors compared between the two stocks. Get Soligenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNGX vs. The Competition Export to ExcelMetricSoligenixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.76M$3.37B$6.14B$10.65BDividend YieldN/A2.29%5.66%4.70%P/E Ratio-0.4721.3485.8427.65Price / Sales63.99470.58621.60138.35Price / CashN/A47.1938.3262.20Price / Book1.0910.4313.066.79Net Income-$8.27M-$52.40M$3.30B$275.88M7 Day Performance39.84%6.36%4.81%2.64%1 Month Performance-33.21%16.14%9.99%9.13%1 Year Performance-55.36%33.90%85.28%35.89% Soligenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNGXSoligenix3.1572 of 5 stars$1.79-1.1%$6.00+235.2%-55.2%$7.76M$120K-0.4720Analyst ForecastGap UpLEXXLexaria Bioscience2.8903 of 5 stars$0.98-6.4%$4.00+307.0%-70.3%$20.54M$460K-1.477News CoverageAnalyst ForecastRVPHReviva Pharmaceuticals3.6909 of 5 stars$0.31+4.5%$4.86+1,475.5%-42.0%$20.45MN/A-0.475Analyst ForecastGap UpTAOXSynaptogenix0.0504 of 5 stars$6.28+7.4%N/AN/A$20.40M$3.96K-0.314News CoveragePositive NewsAnalyst ForecastGap UpSYBXSynlogic0.7514 of 5 stars$1.70-2.3%N/A+18.8%$20.36M$10K-21.2580News CoveragePositive NewsAnalyst ForecastAPLMApollomics0.7843 of 5 stars$18.43+51.3%N/A+29.8%$20.34M$1.49M0.0045Analyst ForecastGap UpHigh Trading VolumeFNCHFinch Therapeutics Group0.7706 of 5 stars$12.25+0.3%N/A+5.2%$19.67MN/A-1.39190CTXRCitius Pharmaceuticals2.7112 of 5 stars$1.18+2.6%$53.00+4,391.5%-86.8%$19.56MN/A0.0020Analyst ForecastGap UpHigh Trading VolumePRPHProPhase Labs0.3595 of 5 stars$0.44-1.1%N/A-77.8%$18.39M$5.59M-0.35130Analyst ForecastGap UpTHARTharimmune2.5079 of 5 stars$2.90-4.0%$17.00+486.2%+56.7%$17.83MN/A-0.482News CoverageAnalyst ForecastASBPAspire BiopharmaN/A$0.31-13.0%N/AN/A$17.80MN/A0.00N/AAnalyst ForecastGap Down Related Companies and Tools Related Companies Lexaria Bioscience Competitors Reviva Pharmaceuticals Competitors Synaptogenix Competitors Synlogic Competitors Apollomics Competitors Finch Therapeutics Group Competitors Citius Pharmaceuticals Competitors ProPhase Labs Competitors Tharimmune Competitors Aspire Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNGX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soligenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
